Platelet aggregation is one of the main functions of platelets, and malignancy enhances platelet aggregation. The disease site is systemic and the associated symptoms are ascites, hypercoagulable state, thrombocytopenia, enhanced platelet aggregation, shortened platelet life span, and thrombocytosis. The etiology of enhanced platelet aggregation is various types of malignant tumors. The different mechanisms of tumor-induced platelet aggregation exist may be ADP-mediated: malignant tumor cells have activating substances that directly promote aggregation and can release ADP that mediates the aggregation response, ADP is formed spontaneously by tumors or released by platelets; thrombus-dependent manner: some tumor cells have metastatic ability consistent with thrombus formation and platelet aggregation ability, thrombus may be due to lipoproteins on the cell surface; thrombin generation The presence of plasma membrane proteins with platelet aggregation activity/procoagulant activity (PAA/PCA) in some tumor cells activates the coagulation system and leads to thrombin generation, which binds to the platelet surface to activate secretion and platelet aggregation; tumor cell membrane glycoproteins: some membrane glycoproteins of tumor cells have been found to be involved in platelet aggregation in recent years, and membrane proteins mediate platelet aggregation in a thrombin-independent manner. However, they are susceptible to inhibition by trypsin. Among the above mechanisms, divalent cations and plasma factors are extremely important for the activity of platelet aggregation induced by tumor cells. Diseases associated with enhanced platelet aggregation include anemia, malignant tumors of the pterygoid sinus, malignant tumors of the ear, malignant tumors of the maxillary sinus, malignant tumors of the septal sinus, malignant tumors of the spermatic cord, primary malignant tumors of the spleen, thrombosis, anemia due to malignancy, malignant tumors of the seminal vesicles, malignant tumors of the parotid gland, and other malignant tumors of the esophagus.